Abstract
Drug-Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% annualized event rate without plateau is observed. The DynamX™ Novolimus-Eluting Coronary Bioadaptor
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have